List of Excipients in Branded Drug ORGOVYX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sumitomo Pharma America Inc	ORGOVYX	relugolix	72974-120	CARNAUBA WAX	2029-01-28
Sumitomo Pharma America Inc	ORGOVYX	relugolix	72974-120	FERRIC OXIDE RED	2029-01-28
Sumitomo Pharma America Inc	ORGOVYX	relugolix	72974-120	HYDROXYPROPYL CELLULOSE	2029-01-28
Sumitomo Pharma America Inc	ORGOVYX	relugolix	72974-120	HYPROMELLOSE 2910	2029-01-28
Sumitomo Pharma America Inc	ORGOVYX	relugolix	72974-120	MAGNESIUM STEARATE	2029-01-28
Sumitomo Pharma America Inc	ORGOVYX	relugolix	72974-120	MANNITOL	2029-01-28

Orgovyx Excipient Strategy and Commercial Opportunities for Relugolix

Last updated: September 24, 2026

Orgovyx is an immediate-release, film-coated oral tablet containing 120 mg of relugolix. Its commercial formulation uses conventional solid-dose excipients rather than a technically complex delivery system. The principal opportunity is therefore not a novel excipient platform. It is the development of bioequivalent generic tablets, differentiated oral presentations, regional products, and manufacturing processes that control relugolix’s dissolution, stability, and exposure profile.

The excipient barrier appears moderate. The larger commercial barriers are relugolix’s pharmacokinetic sensitivity, food and drug-interaction labeling, formulation reproducibility, patent coverage, and the need to match the reference product across a high-dose loading regimen and chronic daily administration.

What excipients are used in Orgovyx tablets?

Orgovyx contains relugolix as the active pharmaceutical ingredient and is supplied as a 120 mg film-coated tablet. The FDA prescribing information identifies the inactive ingredients as mannitol, sodium starch glycolate, hypromellose, croscarmellose sodium, magnesium stearate, titanium dioxide, and ferric oxide red, subject to the specific labeling version and market presentation reviewed [1].

Formulation function	Orgovyx excipient or excipient class	Commercial role
Diluent	Mannitol	Adds tablet mass and supports compressibility and mouthfeel
Disintegrants	Sodium starch glycolate; croscarmellose sodium	Promotes tablet breakup and drug release
Binder or film-forming polymer	Hypromellose	Supports coating and may contribute to mechanical protection
Lubricant	Magnesium stearate	Controls ejection force and manufacturing friction
Opacifier	Titanium dioxide	Supports film-coat opacity and light protection
Colorant	Ferric oxide red	Provides product identification and visual differentiation

The formulation does not depend on an extended-release matrix, enteric coating, liposomal carrier, depot system, or biologic stabilization platform. That reduces the technical complexity of formulation replication, although it does not eliminate bioequivalence risk.

Why does the excipient system matter for relugolix?

Relugolix is administered at 360 mg on the first day followed by 120 mg once daily. A generic developer must reproduce the reference product’s performance under both dosing conditions. Tablet disintegration, wetting, particle dispersion, and dissolution can affect early systemic exposure, particularly during the loading dose.

The excipient system also has practical manufacturing implications:

• Mannitol can improve tablet bulk and patient acceptability but may affect compaction behavior and moisture response.
• Sodium starch glycolate and croscarmellose sodium provide overlapping disintegration functions, allowing optimization of tablet hardness without materially slowing release.
• Magnesium stearate requires controlled blending. Excessive lubrication can reduce wettability and slow dissolution.
• Film-coat pigments can affect appearance, light protection, and coating weight without changing the core release profile.
• Excipient grade, particle-size distribution, residual moisture, and supplier variability can affect scale-up performance.

A successful generic formulation would normally target the same immediate-release profile while minimizing unnecessary departures from the reference product.

What is the FDA regulatory status of Orgovyx?

Orgovyx was approved by the FDA on December 18, 2020, under NDA 214621 for the treatment of adult patients with advanced prostate cancer [1]. It is an oral androgen-deprivation therapy that suppresses gonadotropin-releasing hormone signaling and reduces testosterone production.

Regulatory item	Status
Active ingredient	Relugolix
Brand	Orgovyx
Dosage form	Immediate-release film-coated tablet
Strength	120 mg
FDA approval	December 18, 2020
NDA	214621
Approved indication	Advanced prostate cancer in adult patients
Regimen	360 mg loading dose, then 120 mg once daily
Regulatory pathway for generics	ANDA, subject to reference-product and listing requirements

Orgovyx is a small-molecule product. Biosimilar regulation does not apply. Competitive entry would proceed through an abbreviated new drug application rather than a 351(k) biosimilar application.

When does Orgovyx lose exclusivity?

Orgovyx’s five-year new chemical entity exclusivity began on the December 18, 2020 approval date and generally prevented submission of an ANDA containing a Paragraph IV certification until the five-year period elapsed, subject to statutory timing rules and any applicable patent protections [2].

The practical exclusivity analysis has two separate components:

1. Regulatory exclusivity, including NCE exclusivity.
2. Patent protection, including Orange Book-listed patents, possible patent-term adjustment, and any patent-term extension.

A five-year NCE period does not establish the date of generic launch. Generic entry depends on the expiration or successful challenge of relevant patents, litigation outcomes, settlement terms, pediatric exclusivity, and the first filer’s 180-day exclusivity rights.

Orgovyx exclusivity timeline

Event	Date or assessment
FDA approval	December 18, 2020
Five-year NCE period	Generally runs through December 18, 2025
Earliest typical post-NCE ANDA filing opportunity	After the NCE restriction ends, subject to applicable rules
Earliest commercial generic launch	Depends on patent status, litigation, settlement, and first-filer rights
Biosimilar pathway	Not applicable

The most important commercial mistake is to treat December 2025 as an automatic generic launch date. It is only the end of the principal NCE restriction. The effective entry date must be determined from the current Orange Book, patent litigation docket, and any settlement agreement.

What patents protect Orgovyx and relugolix?

Orgovyx protection can involve several patent categories:

• Composition-of-matter patents covering relugolix or related chemical structures.
• Solid-form, polymorph, salt, or crystallinity patents.
• Pharmaceutical composition patents.
• Manufacturing and purification patents.
• Method-of-use patents covering prostate cancer treatment or androgen-deprivation regimens.
• Combination patents involving other oncology therapies.
• Patents directed to dosing, administration, or treatment sequencing.

The FDA Orange Book is the controlling commercial reference for patents listed against the approved NDA. Patent family records, assignment data, and national-phase filings provide broader context but do not automatically establish Orange Book relevance.

How strong is the Orgovyx patent estate?

The estate is stronger when protection extends beyond a single composition-of-matter patent. A layered estate can delay entry even if a generic developer designs around one claim category. The most commercially relevant questions are:

Question	Business significance
Does a valid composition patent remain in force?	Can block API use by most conventional generics
Are formulation patents listed?	May require a design-around or Paragraph IV challenge
Are method-of-use patents listed?	May support a carve-out or label strategy
Are process patents commercially necessary?	Can increase API supply and manufacturing risk
Are patents enforceable in the target market?	Determines geographic launch exposure
Are claims broad or narrow?	Determines design-around feasibility

Formulation patents are less likely to block all generic development when the reference uses standard excipients. A generic may replace one disintegrant, change the diluent ratio, select a different film-coat system, or alter manufacturing parameters while maintaining bioequivalence. A formulation patent becomes more valuable if it claims a narrow dissolution profile, a critical impurity limit, a specific solid form, or a formulation needed to achieve the approved exposure.

What formulation patents could affect generic Orgovyx entry?

A generic developer should screen at least five technical claim areas.

Immediate-release tablet composition

Claims may cover the active ingredient with specified diluents, disintegrants, lubricants, binders, or coating systems. Standard excipients are easy to substitute individually, but a claim directed to ranges, ratios, or a functional dissolution outcome may be harder to avoid.

Dissolution and bioequivalence

Relugolix formulations may be assessed against dissolution in multiple media. A generic that matches only one buffer condition may still fail to reproduce the reference profile across pH conditions. Formulation work should evaluate:

• Dissolution at acidic, intermediate, and near-neutral pH.
• Tablet hardness and disintegration time.
• Stability after heat and humidity exposure.
• Food-effect performance where relevant.
• API particle size and surface area.
• Excipient grade and supplier changes.

Solid-state control

If relugolix has commercially relevant polymorph or crystallinity constraints, solid-state characterization may be more important than the choice between two conventional disintegrants. XRPD, DSC, TGA, microscopy, and particle-size analysis would normally support control of the active ingredient and finished product.

Manufacturing process

Wet granulation, dry granulation, direct compression, milling, blending order, lubrication time, and coating conditions can all affect dissolution. A process patent may not block a product if an alternative process achieves the same quality profile, but a change in process can create new stability and scale-up risks.

Method-of-use and label carve-outs

Method-of-use patents can affect whether a generic applicant includes the full branded indication. For a product used in advanced prostate cancer, a skinny-label strategy may be commercially limited if the principal indication remains protected or if prescribers routinely use the product for the patented method.

What Paragraph IV challenges and litigation affect Orgovyx?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. If the NDA holder sues within the statutory period after receiving notice, FDA approval may be subject to a 30-month stay, subject to court action and statutory exceptions [2].

The relevant commercial sequence is:

1. Generic applicant files an ANDA.
2. The applicant certifies against listed patents.
3. The applicant sends Paragraph IV notice to the patent holder.
4. The patent holder may file an infringement action.
5. FDA approval may be stayed for up to 30 months.
6. The first filer may obtain 180-day exclusivity if statutory conditions are satisfied.
7. Entry occurs after patent resolution, settlement, or expiration of the relevant barrier.

Publicly reported litigation should be distinguished from patent listing data. A patent can remain listed without an active infringement case, and a case can resolve without removing every listed patent. Commercial diligence should track district-court complaints, claim-construction orders, settlements, dismissals, appeals, and any FDA updates.

Which companies could challenge Orgovyx?

Potential challengers include large generic companies with oncology distribution, API manufacturers with relugolix capabilities, and specialty generic firms that target high-value oral oncology products. The most credible entrants would likely have:

• Controlled access to relugolix API.
• Experience with low-solubility or exposure-sensitive compounds.
• Sufficient clinical and analytical capacity for ANDA development.
• A regulatory team able to manage Paragraph IV litigation.
• Distribution relationships with oncology and urology practices.
• Ability to support a 30-day chronic prescription product.

Potential competition could come from companies such as Teva, Viatris, Sandoz, Sun Pharma, Dr. Reddy’s, Cipla, Lupin, Aurobindo, Zydus, and specialty generic manufacturers. Company-specific entry should not be assumed without an identified ANDA, Paragraph IV notice, court filing, or public development statement.

What commercial opportunities exist for excipient suppliers?

The largest near-term excipient opportunity is supply into generic relugolix development rather than replacement of Orgovyx’s branded formulation.

Excipient substitution

Suppliers can support alternative formulations using:

• Direct-compression mannitol grades.
• Microcrystalline cellulose or other compressible fillers.
• Alternative superdisintegrants.
• Low-moisture or low-peroxide excipient grades.
• Lubricants optimized for rapid release.
• Film-coat systems with equivalent color and opacity.

A supplier that demonstrates consistent performance across multiple API lots can become embedded in a generic formulation before ANDA submission. Switching suppliers after submission can trigger comparability, stability, and regulatory documentation work.

Co-development and technical packages

Excipient companies can offer more than catalog material. Valuable packages include:

• Drug-excipient compatibility data.
• Compaction and ejection profiles.
• Dissolution comparisons across grades.
• Stability data under ICH conditions.
• Scale-up protocols.
• Supplier qualification documentation.
• Regulatory support for DMF or Type IV master-file references where appropriate.

Finished-dose contract manufacturing

Contract manufacturers can produce relugolix tablets for regional licensees or generic companies. The opportunity is strongest for manufacturers that already handle oncology tablets, can segregate potent compounds, and have validated film-coating and high-containment operations.

What manufacturing and IP barriers affect commercial entry?

Relugolix generic entry has four principal barriers.

First, API control may be more difficult than tablet manufacture. The active ingredient must meet impurity, particle-size, solid-state, and residual-solvent specifications.

Second, the dose regimen creates a packaging and labeling challenge. The reference product requires a 360 mg loading dose followed by 120 mg daily dosing. Packaging that reduces loading-dose errors can create a practical commercial advantage.

Third, chronic oral oncology products require reliable supply. A low-cost formulation with inconsistent tablet release or supply interruptions will be unattractive to distributors and health systems.

Fourth, the generic must avoid protected claims without creating a clinically or regulatorily inferior product. Excipients can provide a design-around route, but a design-around must preserve dissolution, stability, tablet robustness, and bioequivalence.

How does Orgovyx compare with competing androgen-deprivation products?

Product	Active ingredient	Route	Formulation complexity	Generic or biosimilar exposure
Orgovyx	Relugolix	Oral daily tablet	Conventional immediate-release tablet	Small-molecule generic risk
Lupron Depot	Leuprolide	Injectable depot	Microsphere or depot technology	Complex injectable and formulation barriers
Firmagon	Degarelix	Injectable depot	Reconstituted injectable depot	Injectable manufacturing barrier
Erleada	Apalutamide	Oral tablet	Conventional solid dose	Small-molecule generic risk
Nubeqa	Darolutamide	Oral tablet	Conventional solid dose	Small-molecule generic risk
Xtandi	Enzalutamide	Oral capsule/tablet	Oral solid dose	Small-molecule generic risk

Orgovyx’s principal commercial differentiation is oral daily administration and avoidance of an injection appointment. Its formulation is less complex than depot injections, which supports generic development. Its clinical and commercial value depends on maintaining adherence, testosterone suppression, and continuity of therapy.

What revenue exposure exists from generic Orgovyx entry?

Generic entry would affect:

• Branded relugolix prescription volume.
• Net price and payer rebates.
• Specialty-pharmacy dispensing economics.
• Co-commercialization revenue.
• Oncology and urology account access.
• International licensing value.
• Potential combination-product or indication expansion.

The impact would likely be gradual if patent settlements permit a limited number of authorized or licensed entrants before broad generic competition. It could be faster if multiple ANDA applicants launch concurrently after patent barriers expire.

The most defensible commercial strategy is to segment the market:

1. Preserve the branded product for patients and prescribers valuing oral administration and established supply.
2. Develop authorized-generic or licensed supply channels.
3. Use excipient and process design to support low-cost regional products.
4. Protect differentiated packaging, adherence tools, and specialty distribution.
5. Evaluate lifecycle formulations only where they create a clinically meaningful or payer-recognized advantage.

Key Takeaways

• Orgovyx is a 120 mg immediate-release relugolix film-coated tablet.
• Its listed excipients are conventional: mannitol, superdisintegrants, hypromellose, magnesium stearate, titanium dioxide, and ferric oxide red.
• The formulation is technically accessible to generic developers, but dissolution, API solid state, food-effect performance, and manufacturing reproducibility remain important.
• FDA approval occurred on December 18, 2020. The five-year NCE period generally ran through December 18, 2025.
• Orgovyx is a small molecule, so biosimilar competition does not apply.
• Patent risk must be assessed through current Orange Book listings, patent families, Paragraph IV notices, litigation, and settlements.
• The strongest excipient opportunities are generic formulation co-development, technical-grade supply, bioequivalence support, and contract manufacturing.
• Packaging that handles the 360 mg loading dose and 120 mg maintenance dose can create commercial differentiation.
• Generic launch timing cannot be inferred from NCE expiration alone.

FAQs

Can a generic Orgovyx use different excipients?

Yes. An ANDA applicant can generally use different inactive ingredients if the formulation meets applicable safety, quality, dissolution, labeling, and bioequivalence requirements and does not infringe valid patent claims.

Is Orgovyx an extended-release product?

No. Orgovyx is labeled as an immediate-release film-coated tablet. Its formulation does not rely on an extended-release matrix or depot delivery system.

Does Orgovyx have biosimilar risk?

No. Relugolix is a chemically synthesized small molecule. Competitive products would be reviewed primarily through the ANDA pathway rather than the biosimilar pathway.

Can a generic developer change the Orgovyx film coating?

Usually, a developer can select an alternative film-coat system if it preserves product quality, identification, stability, and bioequivalence and avoids protected formulation claims.

What is the most valuable excipient opportunity around relugolix?

The highest-value opportunity is a validated excipient and process package that improves dissolution consistency, scale-up performance, and stability while supporting a non-infringing generic formulation.

References

1. U.S. Food and Drug Administration. (2020). Orgovyx (relugolix) prescribing information, NDA 214621.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certification requirements.
4. Myovant Sciences GmbH. (2023). Annual report and securities filings.
5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary.